Compugen (CGEN)vsRevolution Medicines Inc (RVMD)
CGEN
Compugen
$2.47
+0.41%
HEALTHCARE · Cap: $233.97M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Compugen generates 9873% more annual revenue ($74.00M vs $742,000). CGEN leads profitability with a 47.6% profit margin vs 0.0%. CGEN earns a higher WallStSmart Score of 60/100 (C+).
CGEN
Buy60
out of 100
Grade: C+
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Keeps 48 of every $100 in revenue as profit
Revenue surging 107.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -339.6%
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 47.6% and operating margin at -339.6%. Revenue growth of 107.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap, Altman Z-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
CGEN profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
CGEN carries more volatility with a beta of 2.79 — expect wider price swings.
CGEN is growing revenue faster at 107.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CGEN scores higher overall (60/100 vs 24/100), backed by strong 47.6% margins and 107.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?